Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Common Equity (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Common Equity for 4 consecutive years, with $53.6 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 62.54% to $53.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.6 million through Dec 2025, up 62.54% year-over-year, with the annual reading at $53.6 million for FY2025, 62.54% up from the prior year.
  • Common Equity for Q4 2025 was $53.6 million at Orchestra BioMed Holdings, up from $43.7 million in the prior quarter.
  • The five-year high for Common Equity was $99.8 million in Q1 2023, with the low at $78000.0 in Q1 2022.
  • Average Common Equity over 4 years is $51.0 million, with a median of $53.1 million recorded in 2022.
  • The sharpest move saw Common Equity skyrocketed 127787.18% in 2023, then plummeted 99.33% in 2025.
  • Over 4 years, Common Equity stood at $52.5 million in 2022, then grew by 29.52% to $68.0 million in 2023, then crashed by 51.56% to $33.0 million in 2024, then surged by 62.54% to $53.6 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $53.6 million, $43.7 million, and $295000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.